Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Open Forum Infectious Diseases
|
October 27, 2022
Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
Ana Strezova, Javier Diez-Domingo, Kamal Al Shawafi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 19, 2023
No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial
Abdi Naficy, Adrienne Kuxhausen, Paola Pirrotta, et al.
The Journal of Infection
|
August 8, 2025
Herpes zoster recurrence, and safety and immunogenicity of the recombinant zoster vaccine in adults aged ≥50 years with a history of herpes zoster: A phase 3, randomized controlled trial
Bisi Jegede, Yingjun Zhou, Helen Hawksworth, et al.
The Journal of Infection
|
May 15, 2026
Long-term immunogenicity and safety of RZV primary vaccination and revaccination in kidney transplant recipients
Melinda M Hutton, Peter E Vink, Adrienne Kuxhausen, et al.
The Journal of Biological Chemistry
|
December 4, 2004
Targeting a novel Plasmodium falciparum purine recycling pathway with specific immucillins
Li-Min Ting, Wuxian Shi, Andrzej Lewandowicz, et al.
The Journal of Clinical Investigation
|
February 9, 2021
Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice
Sara A Healy, Charles Anderson, Bruce J Swihart, et al.
Eclinicalmedicine
|
July 9, 2025
Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications
Ana Strezova, Javier Díez Domingo, Anthony L Cunningham, et al.
Open Forum Infectious Diseases
|
June 5, 2026
Safety and Immunogenicity of 1 or 2 Additional Doses of the Adjuvanted Recombinant Zoster Vaccine Administered 5-6 Years After Primary Vaccination in Adults ≥50 Years
Rafael Leon, Javier Diez-Domingo, Charles Andrews, et al.
The Lancet. Infectious Diseases
|
August 17, 2024
Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
Halimatou Diawara, Sara A Healy, Agnes Mwakingwe-Omari, et al.
The Lancet. Infectious Diseases
|
November 21, 2021
Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial
Mahamadou S Sissoko, Sara A Healy, Abdoulaye Katile, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Open Forum Infectious Diseases
|
October 27, 2022
Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
Ana Strezova, Javier Diez-Domingo, Kamal Al Shawafi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 19, 2023
No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial
Abdi Naficy, Adrienne Kuxhausen, Paola Pirrotta, et al.
The Journal of Infection
|
August 8, 2025
Herpes zoster recurrence, and safety and immunogenicity of the recombinant zoster vaccine in adults aged ≥50 years with a history of herpes zoster: A phase 3, randomized controlled trial
Bisi Jegede, Yingjun Zhou, Helen Hawksworth, et al.
The Journal of Infection
|
May 15, 2026
Long-term immunogenicity and safety of RZV primary vaccination and revaccination in kidney transplant recipients
Melinda M Hutton, Peter E Vink, Adrienne Kuxhausen, et al.
The Journal of Biological Chemistry
|
December 4, 2004
Targeting a novel Plasmodium falciparum purine recycling pathway with specific immucillins
Li-Min Ting, Wuxian Shi, Andrzej Lewandowicz, et al.
The Journal of Clinical Investigation
|
February 9, 2021
Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice
Sara A Healy, Charles Anderson, Bruce J Swihart, et al.
Eclinicalmedicine
|
July 9, 2025
Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications
Ana Strezova, Javier Díez Domingo, Anthony L Cunningham, et al.
Open Forum Infectious Diseases
|
June 5, 2026
Safety and Immunogenicity of 1 or 2 Additional Doses of the Adjuvanted Recombinant Zoster Vaccine Administered 5-6 Years After Primary Vaccination in Adults ≥50 Years
Rafael Leon, Javier Diez-Domingo, Charles Andrews, et al.
The Lancet. Infectious Diseases
|
August 17, 2024
Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
Halimatou Diawara, Sara A Healy, Agnes Mwakingwe-Omari, et al.
The Lancet. Infectious Diseases
|
November 21, 2021
Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial
Mahamadou S Sissoko, Sara A Healy, Abdoulaye Katile, et al.
Page
of 3